Quantcast

Latest Infliximab Stories

2014-07-07 16:02:23

Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

2014-06-03 12:39:19

Leveraging Nurse Support Could Boost Engagement with Rheumatoid Arthritis Brands, According to Findings in New Manhattan Research Analysis from Decision Resources Group BURLINGTON, Mass., June

2014-06-01 23:01:09

LifeScienceIndustryResearch.com adds Latest Report on “Frontier Pharma: Psoriasis – Identifying and Commercializing First-in-Class Innovation” to its store. Dallas,

2014-05-14 12:31:58

LONDON, May 14, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

2014-05-14 08:28:16

LONDON, May 14, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

2014-05-13 00:21:38

- This Is First Study to Demonstrate Clinical Benefit of Oral alpha 4 Integrin Antagonist in Patient with Inflammatory Bowel Disease - TOKYO, May 13, 2014 /PRNewswire/ -- Ajinomoto

2014-05-05 12:28:40

European Dermatologists Indicate that Fewer than Half of Their Severe Patients are being Treated with a Biologic, According to Findings from Decision Resources Group BURLINGTON, Mass., May

2014-04-30 10:21:24

The adhesion molecule CD146 plays a vital role in inflammation and offers a promising therapeutic target for treating inflammatory bowel disease (IBD) as well as preventing colitis-associated colorectal cancer, say scientists.